Porton Pharma Solutions, a leading contract development and manufacturing organisation (CDMO), has partnered with Dragon Sail Pharmaceutical to integrate resources and expertise in ADC development. The agreement, signed in Guilin, China, brings together Porton’s advanced technology platforms in ADC drug
Exclusive event for senior external manufacturing leaders. Boston, January 2026
This report summarises the key factors driving price changes at the end of the 2024, and into the new year: Biologics contract manufacturing The global biologics contract manufacturing (biopharma CMO) market is expected to record a CAGR of 10.3% over
“Gene editing and cell therapy, they’re going to be entrenched modalities, much like small molecules and antibodies are today, that will fundamentally reshape healthcare.” says Devyn Smith. Devyn Smith, CEO of Arbor Biotechnologies and Chairman of the Alliance for Regenerative
Simtra BioPharma Solutions, a pharmaceutical manufacturing company, is investing $250 million to expand its sterile fill/finish manufacturing campus in Bloomington, Indiana. The expansion, supported by a $500,000 allocation from the state’s Regional Economic Acceleration and Development Initiative (READI) 2.0, will
Aadi Bioscience, Inc. has entered into a significant licensing agreement with WuXi Biologics and HANGZHOU DAC Biotechnology Co., Ltd., aimed at developing and commercialising a portfolio of next-generation antibody-drug conjugates (ADCs). This collaboration gives Aadi exclusive rights to three preclinical
Aramis Biotechnologies and Biodextris Inc. have formed a strategic partnership to advance the production of a seasonal influenza vaccine, focusing on supporting clinical trials and addressing the need for better protection of at-risk populations. The agreement will see Biodextris, a
Accelerated Biosciences and Stemmatters have entered into a strategic partnership to advance the development and commercialisation of human induced pluripotent stem cells (iPSC) derived from human trophoblast stem cells (hTSC). The collaboration will focus on leveraging Accelerated Biosciences’ innovative hTSC
PolyPeptide Group AG , a global CDMO specialising in peptide-based active pharmaceutical ingredients, has announced the commencement of production at its newly commissioned solid-phase peptide synthesis (SPPS) capacity in Braine-l’Alleud, Belgium. The €100 million facility represents the largest single investment
Lifecore Biomedical, Inc. has announced a new agreement with Nirsum Laboratories, Inc. to support the clinical development of Nirsum’s lead candidate, NRS-033. The collaboration will focus on fill and finish technology transfer, a key component in the development and commercialisation
